Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Capital Reinvestment Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Capital Reinvestment Ratio of 1.44x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥11.57 Million) in capital expenditures (CN¥16.64 Million). Check Hubei Biocause Heilen Pharmaceutical Co. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Capital Reinvestment Ratio (2018–2025)
This chart tracks Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Hubei Biocause Heilen Pharmaceutical Co..
Annual Capital Reinvestment Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year Capital Reinvestment Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2018 to 2025. See cash generation quality of Hubei Biocause Heilen Pharmaceutical Co. to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 6.93x | CN¥7.55 Million | CN¥52.33 Million | ▲ +304.9% |
| 2024 | 1.71x | CN¥96.07 Million | CN¥164.43 Million | ▲ +25.8% |
| 2023 | 1.36x | CN¥137.06 Million | CN¥186.53 Million | ▲ +349.4% |
| 2022 | 0.30x | CN¥250.79 Million | CN¥75.95 Million | ▲ +78.2% |
| 2021 | 0.17x | CN¥123.98 Million | CN¥21.07 Million | ▲ +54.4% |
| 2020 | 0.11x | CN¥121.67 Million | CN¥13.39 Million | ▲ +26.7% |
| 2019 | 0.09x | CN¥372.33 Million | CN¥32.34 Million | ▼ -73.6% |
| 2018 | 0.33x | CN¥76.18 Million | CN¥25.08 Million | — |